scholarly journals Yellow fever vaccine, recombinant envelope protein (rYFE), plant derived, for active immunization: pre-clinical studies in mice and monkey models

2016 ◽  
Author(s):  
Rosane Guimarães ◽  
André Fernandes ◽  
Marisol Simões ◽  
Renato Marchevsky ◽  
Patrícia Neves ◽  
...  
Keyword(s):  
Yellow Fever ◽  
Envelope Protein ◽  
Clinical Studies ◽  
Active Immunization ◽  
Yellow Fever Vaccine ◽  
Vaccine Recombinant ◽  
Recombinant Envelope Protein

Variation in the biological function of envelope protein epitopes of yellow fever vaccine viruses detected with monoclonal antibodies

Biologicals ◽  
1992 ◽  
Vol 20 (2) ◽  
pp. 117-128 ◽  
Author(s):  
T.N. Ledger ◽  
B.K. Sil ◽  
M.R. Wills ◽  
G. Lewis ◽  
R.M. Kinney ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Yellow Fever ◽  
Envelope Protein ◽  
Biological Function ◽  
Yellow Fever Vaccine

Corneal Graft Rejection after Yellow Fever Vaccine: A Case Report

2021 ◽  
pp. 1-4
Author(s):  
Roberto Vignapiano ◽  
Lidia Vicchio ◽  
Eleonora Favuzza ◽  
Michela Cennamo ◽  
Rita Mencucci
Keyword(s):  
Case Report ◽  
Yellow Fever ◽  
Graft Rejection ◽  
Corneal Graft ◽  
Yellow Fever Vaccine ◽  
Corneal Graft Rejection

Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?

2021 ◽  
pp. 135245852110063
Author(s):  
Caroline Papeix ◽  
Julie Mazoyer ◽  
Elisabeth Maillart ◽  
Caroline Bensa ◽  
Anne-Laure Dubessy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Study ◽  
Yellow Fever ◽  
Yellow Fever Vaccine ◽  
Relapsing Remitting ◽  
Annualized Relapse Rate ◽  
National Cohort ◽  
First Relapse ◽  
Yellow Fever Vaccination ◽  
Relapsing Remitting Multiple Sclerosis

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53–3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.

scholarly journals Thinking about Yellow Fever Vaccine age limit

2020 ◽  
Vol 101 ◽  
pp. 450
Author(s):  
D.E. Iglesias ◽  
C. Ezcurra ◽  
N. Garcia Allende ◽  
A.V. Sanchez ◽  
A. Risso Patrón ◽  
...  
Keyword(s):  
Yellow Fever ◽  
Yellow Fever Vaccine ◽  
Age Limit

scholarly journals Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals

2021 ◽  
Author(s):  
Laura Ramos de Almeida ◽  
Roberta Fachini Criado ◽  
Paulo Ricardo Criado ◽  
Luis Felipe Ensina ◽  
Beatrice Martinez Zugaib Abdalla ◽  
...  
Keyword(s):  
Adverse Events ◽  
Yellow Fever ◽  
Chronic Urticaria ◽  
Yellow Fever Vaccine ◽  
Healthy Individuals
Sign in / Sign up

Export Citation Format

Share Document